SeaStar Medical Holding Corporation (Nasdaq: ICU), a
commercial-stage medical device company developing proprietary
solutions to reduce the consequences of hyperinflammation on vital
organs, estimates a U.S. total addressable market for its
proprietary, patented Selective Cytopheretic Device (SCD) in five
clinical indications, subject to U.S. Food & Drug
Administration (FDA) approvals, of $25 to $33 billion.
The following chart summarizes ranges of the
adult SCD total addressable market and estimated clinical trial
costs, by indication:
Clinical Indication |
Annual U.S. Patient
Population1 |
Total Addressable U.S. Market$ in millions2 |
Clinical Trial Costs$ in millions |
Adult Acute Kidney Injury (AKI)3 |
210,000 |
4,700 – 6,300 |
154 |
Cardiorenal Syndrome with no LVAD5 |
580,000 |
13,100 -17,400 |
5 |
Adult Acute Respiratory Distress Syndrome (ARDS) |
200,000 |
4,500 – 6,000 |
10 |
Adult Hepatorenal Syndrome2 |
50,000 |
1,100 – 1,500 |
4 |
Cardiorenal Syndrome with LVAD2, 4 |
60,000 |
1,400 – 1,800 |
4 |
“The estimated size of these U.S. markets versus
our projected clinical trial costs clearly warrant pursuing FDA
approvals in these indications. The ability to use the SCD as
currently configured, without alteration for each new indication,
allows us to cost-efficiently approach the total addressable
market. Additionally, we expect future commercial sales for the SCD
in adult AKI to help cover clinical trial costs,” said Eric
Schlorff, SeaStar Medical CEO. “We have already reached a major
regulatory milestone in securing approval for the SCD-Pediatric,
branded as QUELIMMUNE™, for treating critically ill children with
AKI and sepsis. It is highly unusual for a company to gain approval
in a pediatric indication before the adult indication, which we
believe provides support for future SCD regulatory approvals.”
The SCD has been awarded FDA Breakthrough Device
Designation (BDD) in three of the five indications included in the
chart above, namely adult AKI, hepatorenal syndrome and cardiorenal
syndrome with LVAD. The SCD was also awarded BDD for chronic
dialysis in November 2024. The BDD designation holds numerous
benefits including enhanced access to FDA resources resulting in
faster development, as well as priority review by the FDA, early
access to patients and the potential for differentiated market
positioning. The company recently submitted a clinical trial
protocol for chronic dialysis to the FDA for review. Feedback from
the FDA will provide SeaStar Medical with the information necessary
to appropriately estimate the clinical costs and market size for
this indication.
Conference Call
As a reminder, SeaStar Medical management will
hold a conference call today beginning at 4:30 p.m. Eastern time
(1:30 p.m. Pacific time) to discuss business progress and provide
updates. Participants can pre-register for the conference call
here. Those who pre-register will be given a conference passcode
and unique PIN to gain immediate access to the call and bypass the
live operator. Participants may pre-register at any time, including
up to and after the call start time. Those who do not pre-register
can access the live conference call by dialing 866-777-2509 within
the U.S. or 412-317-5413 from outside the U.S., and requesting the
SeaStar Medical call.
A webcast of the conference call will be
available live and archived here. A replay of the call will be
available for 48 hours beginning two hours after its completion by
dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada
or 412-317-0088 from outside the U.S., and entering conference ID
3855739.
Selective Cytopheretic
Device
The Selective Cytopheretic Device (SCD) is a
patented cell-directed extracorporeal device that employs
immunomodulating technology to selectively target proinflammatory
neutrophils and monocytes during continuous renal replacement
therapy (CRRT) and reduces the hyperinflammatory milieu including
the cytokine storm. Unlike pathogen removal and other
blood-purification tools, the SCD is integrated with CRRT
hemofiltration systems to selectively target and transition
proinflammatory monocytes to a reparative state and promote
activated neutrophils to be less inflammatory. This unique
immunomodulation approach may promote long-term organ recovery and
eliminate the need for future renal replacement therapy (RRT),
including dialysis.
The SCD-Pediatric device, QUELIMMUNE, is being
commercialized following FDA approval for children with AKI and
sepsis or septic condition weighing 10 kilograms or more who are
being treated in the ICU with RRT. QUELIMMUNE was approved in
February 2024 under a Humanitarian Device Exemption (HDE)
application, having met the applicable criteria with clinical
results showing safety and probable clinical benefit in a limited
population of critically ill children with AKI who have few
treatment options.
ADULT Acute Kidney Injury Pivotal
Trial
The NEUTRALIZE-AKI (NEUTRophil
and monocyte deActivation via
SeLective Cytopheretic Device – a
randomIZEd clinical trial in Acute Kidney Injury)
is expected to enroll up to 200 adults with 69 subjects enrolled to
date. The trial’s primary endpoint is a composite of 90-day
mortality or dialysis dependency among patients treated with SCD in
addition to CRRT as the standard of care, compared with the control
group receiving only CRRT standard of care. Secondary endpoints
include mortality at 28 days, ICU-free days in the first 28 days,
major adverse kidney events at Day 90 and dialysis dependency at
one year. The study will also include subgroup analyses to explore
the effectiveness of SCD therapy in AKI patients with sepsis and
acute respiratory distress syndrome.
About SeaStar Medical
SeaStar Medical is a commercial-stage medical
technology company that is redefining how extracorporeal therapies
may reduce the consequences of excessive inflammation on vital
organs. SeaStar Medical’s novel technologies rely on science and
innovation to provide life-saving solutions to critically ill
patients. The Company is developing and commercializing
cell-directed extracorporeal therapies that target the effector
cells that drive systemic inflammation, causing direct tissue
damage and secreting a range of pro-inflammatory cytokines that
initiate and propagate imbalanced immune responses. For more
information visit www.seastarmedical.com or visit us on LinkedIn or
X.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation, the
ability of the SCD to treat patients with AKI and other diseases;
the total addressable market for adult SCD applications including
the annual U.S. patient population, cartridge pricing and the
number of cartridges used per patient; the ability of SeaStar
Medical to gain market share and generate sales with respect to the
total addressable market for adult SCD application; anticipated
patient enrollment and the expansion of the clinical trial sites;
the number of patients and annual sales for the addressable AKI
market; the anticipated Medicare and Medicaid reimbursement by CMS
for patients enrolled in clinical trials; planned and potential
future clinical trials and associated costs; the expected
regulatory approval process and timeline for commercialization of
our clinical products; and the ability of SeaStar Medical to meet
the expected timeline. Words such as “believe,” “project,”
“expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside SeaStar Medical’s control and are
difficult to predict. Factors that may cause actual future events
to differ materially from the expected results include, but are not
limited to: (i) the risk that SeaStar Medical may not be able to
obtain regulatory approval of its SCD product candidates; (ii) the
risk that SeaStar Medical may not be able to raise sufficient
capital to fund its operations, including current or future
clinical trials; (iii) the risk that SeaStar Medical and its
current and future collaborators are unable to successfully develop
and commercialize its products or services, or experience
significant delays in doing so, including failure to achieve
approval of its products by applicable federal and state
regulators, (iv) the risk that SeaStar Medical may never achieve or
sustain profitability; (v) the risk that SeaStar Medical may not be
able to access funding under existing agreements; (vi) the risk
that third-parties suppliers and manufacturers are not able to
fully and timely meet their obligations, (vii) the risk of product
liability or regulatory lawsuits or proceedings relating to SeaStar
Medical’s products and services, (viii) the risk that SeaStar
Medical is unable to secure or protect its intellectual property,
(ix) the risk that SeaStar Medical is unable to compete with
larger, better capitalized competitors within the total addressable
market for our products and product candidates; and (ix) other
risks and uncertainties indicated from time to time in SeaStar
Medical’s Annual Report on Form 10-K, including those under the
“Risk Factors” section therein and in SeaStar Medical’s other
filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:
Alliance Advisors IRJody Cain(310)
691-7100Jcain@allianceadvisors.com
# # #
1 Estimates of Annual U.S. Patient Population
and Total Addressable U.S. Market were derived from Silver SA,
Chertow, GM Nephron 2017; 137 (4) 297-301; American College of
Physicians, ACP Hospitalist, Coding information from July 2019;
Sepanlou, et al. Lancet Gastroenterology & Hepatology, 2020
Mar;5(3):245-266; and Orman, et al JAMA Netw Open. 2019 Oct
2;2(10):e19136732 Ranges reflect assumptions regarding cartridge
pricing and number of cartridges used per patient3 FDA Breakthrough
Device Designation received4 Some clinical trial costs have already
been incurred5 LVAD = left ventricular assist device
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
Von Dez 2023 bis Dez 2024